A new type of prodrug of catecholamines: An opportunity to improve the treatment of Parkinson's disease

Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2002, Pages 2349-2351

  Venhuis, Bastiaan J ^a   Wikström, Håkan V ^a   Rodenhuis, Nienke ^a   Sundell, Staffan ^b   Dijkstra, Durk ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 6,7 DIHYDROXYTETRALIN; ADROGOLIDE; APOMORPHINE; CATECHOLAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PD 148903; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG CHOICE; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; MALE; NONHUMAN; OXIDATION; PARKINSON DISEASE; RAT;

2-NAPHTHYLAMINE; ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; CATECHOLAMINES; CRYSTALLOGRAPHY, X-RAY; MALE; MICRODIALYSIS; MOLECULAR CONFORMATION; PARKINSON DISEASE; PRODRUGS; RATS; RATS, WISTAR; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDRONAPHTHALENES;

EID: 0037030601     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025508m     Document Type: Article

References (20)

1. 3,4-Dihydroxyphenylalanine and 5-hydroxy-tryptophan as reserpine antagonists
2. Relative effects of L-DOPA and its methyl ester given orally or intraperitoneally to reserpine-treated mice
3. History of levodopa and dopamine agonists in Parkinson's disease treatment
4. Adjuncts to levodopa therapy: Dopamine agonists
5. Dopamine agonists in the treatment of Parkinson's disease - Past, present and future
6. 2-like dopamine receptor systems
7. Apomorphine in the treatment of Parkinson's disease
8. Enone prodrugs of hydroxylated aminotetralins: PD148903, derivatives and analogs
9. A new dopaminergic prodrug
10. Improved delivery through biological membranes. XIII. Brain-specific delivery of dopamine with a dihydropyridine in equilibrium with pyridinium salt type redox delivery system
11. Tissue levels of N-n-propylnorapomorphine after treatment with (-)-10,11-methylenedioxy-N-n-propylnoraporphine, an orally long-acting prodrug active at central dopamine receptors
12. Carbamate ester prodrugs of dopaminergic compounds: Synthesis, stability, and bioconversion
13. 1 receptor agonist prodrug, has efficacy in Parkinson's disease
14. Adrogilide HCl (ABT-431; DAS-431), a prodrug of the dopamine D(1) receptor agonist, a-86929: Preclinical pharmacology and clinical data
15. Dihydroanalogues of 5- and 7-hydroxy-2-aminotetralins: Synthesis and dopaminergic activity
16. 2 activity of R-(-)-apomorphine and selected analogs: A microdialysis study
17. Neuropharmacological evaluation of a new dopaminergic prodrug with anti-parkinsonian potential
18. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats
19. Cerebral dopamine agonist properties of some 2-aminotetralin derivatives after peripheral and intracerebral administration